Mahzi Therapeutics
CLOSING SOON: Developing precision therapies for genetic disorders affecting children
https://wefunder.com/mahzi.therapeutics
Total raised on Wefunder: 352522
Total investors: 147
Quick facts
- $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
- Completing patient enrollment in first-ever gene therapy clinical trial for Pitt-Hopkins syndrome
- CEO with 20+ years of experience at Merck and rare disease pioneers Genzyme & Ultragenyx
- Leadership team from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
- Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
- $60M raised from leading VCs Venrock, HealthCap, Droia Ventures & HBM Partners
- ️ Forbes 2026 Feature: “This Biotech Lets Families Invest in its Gene Therapy”
- Targeting a $16B market with 800+ rare neurogenetic addressable disorders